Abstract：
UNASSIGNED: To describe the frequency of uveitis recurrences in patients with non-infectious uveitis treated with the biosimilar infliximab-dyyb.
UNASSIGNED: Retrospective case series.
UNASSIGNED: Records of uveitis patients treated with the biosimilar infliximab-dyyb between 2016 and 2022 at two institutions were reviewed. Data extracted included patient demographics, diagnosis, previous originator infliximab use, additional immunosuppression medications, infliximab-dyyb use, reason for switch, disease activity, and follow-up time.
UNASSIGNED: A total of 14 patients were identified. Seven patients were switched from originator infliximab to a biosimilar for nonmedical/non-ocular reasons (insurance prompted the switch). One patient was started directly on infliximab-dyyb due to active joint disease despite well-controlled uveitis. None of these eight patients developed inflammation after the switch. Six patients were started directly on infliximab-dyyb due to poorly controlled uveitis. Of these, five patients achieved disease quiescence during follow-up. The mean dose of originator was 1.79 mg/kg/week, with a median dosing schedule of 4 weeks prior to therapy with infliximab-dyyb. The mean final infliximab-dyyb dosage was 1.81 mg/kg/week, with a median dosing schedule of 4 weeks.
UNASSIGNED: Infliximab-dyyb appears to be efficacious in achieving and maintaining uveitis control.
UNASSIGNED: Retrospective case series.
UNASSIGNED: Records of uveitis patients treated with the biosimilar infliximab-dyyb between 2016 and 2022 at two institutions were reviewed. Data extracted included patient demographics, diagnosis, previous originator infliximab use, additional immunosuppression medications, infliximab-dyyb use, reason for switch, disease activity, and follow-up time.
UNASSIGNED: A total of 14 patients were identified. Seven patients were switched from originator infliximab to a biosimilar for nonmedical/non-ocular reasons (insurance prompted the switch). One patient was started directly on infliximab-dyyb due to active joint disease despite well-controlled uveitis. None of these eight patients developed inflammation after the switch. Six patients were started directly on infliximab-dyyb due to poorly controlled uveitis. Of these, five patients achieved disease quiescence during follow-up. The mean dose of originator was 1.79 mg/kg/week, with a median dosing schedule of 4 weeks prior to therapy with infliximab-dyyb. The mean final infliximab-dyyb dosage was 1.81 mg/kg/week, with a median dosing schedule of 4 weeks.
UNASSIGNED: Infliximab-dyyb appears to be efficacious in achieving and maintaining uveitis control.
摘要：
■描述用生物类似药英夫利昔单抗-dyyb治疗的非感染性葡萄膜炎患者葡萄膜炎复发的频率。
■回顾性病例系列。
■回顾了2016年至2022年在两个机构接受生物仿制药英夫利昔单抗-dyyb治疗的葡萄膜炎患者的记录。提取的数据包括患者人口统计学，诊断,以前的发起人英夫利昔单抗使用，额外的免疫抑制药物，英夫利昔单抗-dyyb使用，转换的原因，疾病活动,和后续时间。
■共确认14例患者。由于非医学/非眼部原因，七名患者从鼻祖英夫利昔单抗转换为生物仿制药（保险提示转换）。尽管葡萄膜炎得到了良好控制，但由于活动性关节病，一名患者直接开始接受英夫利昔单抗-dyyb治疗。转换后，这八名患者均未出现炎症。由于葡萄膜炎控制不佳，六名患者直接开始接受英夫利昔单抗-dyyb治疗。其中,5例患者在随访期间实现疾病静止。鼻祖的平均剂量为1.79mg/kg/周，英夫利昔单抗-dyyb治疗前的中位给药方案为4周。英夫利昔单抗-dyyb的平均最终剂量为1.81mg/kg/周，中位给药方案为4周。
■英夫利昔单抗-dyyb似乎在实现和维持葡萄膜炎控制方面有效。
■回顾性病例系列。
■回顾了2016年至2022年在两个机构接受生物仿制药英夫利昔单抗-dyyb治疗的葡萄膜炎患者的记录。提取的数据包括患者人口统计学，诊断,以前的发起人英夫利昔单抗使用，额外的免疫抑制药物，英夫利昔单抗-dyyb使用，转换的原因，疾病活动,和后续时间。
■共确认14例患者。由于非医学/非眼部原因，七名患者从鼻祖英夫利昔单抗转换为生物仿制药（保险提示转换）。尽管葡萄膜炎得到了良好控制，但由于活动性关节病，一名患者直接开始接受英夫利昔单抗-dyyb治疗。转换后，这八名患者均未出现炎症。由于葡萄膜炎控制不佳，六名患者直接开始接受英夫利昔单抗-dyyb治疗。其中,5例患者在随访期间实现疾病静止。鼻祖的平均剂量为1.79mg/kg/周，英夫利昔单抗-dyyb治疗前的中位给药方案为4周。英夫利昔单抗-dyyb的平均最终剂量为1.81mg/kg/周，中位给药方案为4周。
■英夫利昔单抗-dyyb似乎在实现和维持葡萄膜炎控制方面有效。
